Biomarkers are important for monitoring the progression and effective treatment of diseases such as prostate cancer which are heterogeneous in nature ranging from slowly developing to highly aggressive. Existing diagnostic tools imperfectly diagnose disease aggressiveness, therefore additional biomarkers are required that can help identify patients with lethal disease who require more intense treatment. Coming up with a general approach to identify such biomarkers is what Sandra Goetze and her colleagues set out to do in their work published in Clinical Proteomics. They combined the use of mass spectrometry, to verify proteins present in the serum of prostate cancer patients, with Enzyme-linked immunosorbent assays (ELISAs) to validate and measure levels of the identified protein markers. The approach, named Mass Spectrometry-GUided Immunoassay Development (MS-GUIDE), is generally applicable and can be used in other disease settings as well. If you are interested in the use of mass spectrometry and how it can be combined with other techniques to accelerate translational biomarker research, then this in silico talk is a must-watch!

About the in silico talks series – The latest in bioinformatics by SIB Scientists

The in silico talks online series aims to inform bioinformaticians, life scientists and clinicians about the latest advances led by SIB Scientists on a wide range of topics in bioinformatics methods, research and resources. Stay abreast of the latest developments, get exclusive insights into recent papers, and discover how these advances might help you in your work or research, by subscribing to the in silico talks mailing list.


Goetze S et al. Use of MS-GUIDE for identification of protein biomarkers for risk stratifcation of patients with prostate cancer. Clinical Proteomics